Bcl-2 Proteins: Pioneering Targets in Cancer Immunotherapy

The Bcl-2 family of proteins, known for their crucial role in regulating apoptosis, present an intriguing opportunity for advancing cancer immunotherapy. Recent studies have highlighted their involvement in cellular senescence and survival, particularly in the context of tetraploidization. This research topic aims to explore the dual role of Bcl-2 proteins in cancer cell survival and immune evasion, with a focus on their potential as targets for novel immunotherapeutic strategies. By understanding how these proteins modulate apoptosis and senescence, researchers can uncover new pathways for enhancing the immune system's ability to recognize and eliminate cancer cells. This topic will deal with--historical breakthroughs in apoptosis research--current debates on Bcl-2's role in cancer immunity--innovative methodologies for targeting the Bcl-2 family of proteins in immunotherapy. By bridging the gap between apoptosis and immunity, this research could lead to significant advances in personalized cancer treatments, aligning with the journal's mission to enhance cancer immunotherapy and improve patient outcomes.Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic. Topic editors: Laura Senovilla, Michael Diamantidis Source: https://www.frontiersin.org/research-topics/76937/bcl-2-proteins-pioneering-targets-in-cancer-immunotherapy